Leadership Overview
Lilly has 10 executives leading key functions including finance, marketing, and operations.
Driven by research and innovation, Lilly is dedicated to discovering, developing, and delivering life-changing medicines to patients worldwide, focusing on critical therapeutic areas to improve global health outcomes.
Driven by research and innovation, Lilly is dedicated to discovering, developing, and delivering life-changing medicines to patients worldwide, focusing on critical therapeutic areas to improve global health outcomes.
Leadership Roles at Lilly
Peter Hoogerhuis - Global Chief Financial Officer, Commercial Oncology BU (Ed)
Peter Hoogerhuis, the Global Chief Financial Officer, Commercial Oncology BU (Ed) at Lilly, directs financial strategy and operations for the commercial oncology business unit. This leadership position involves overseeing all financial aspects, including budgeting, forecasting, and resource allocation, to support the unit's growth and profitability objectives. Hoogerhuis ensures robust financial controls and drives fiscal discipline across the oncology commercial operations. The role demands close collaboration with commercial leaders to align financial plans with market strategies and product launches. Peter Hoogerhuis's financial acumen is critical for optimizing investment in research and development pipelines and maximizing the commercial success of oncology therapies. This executive function supports Lilly's broader mission of delivering innovative medicines to patients facing cancer.
Kecia Patton - Vice President, Chief Financial Officer - Neuroscience Business Unit
Kecia Patton, the Vice President, Chief Financial Officer - Neuroscience Business Unit at Lilly, spearheads financial planning and analysis for the neuroscience division. This executive role encompasses managing financial performance, driving strategic financial initiatives, and ensuring fiscal accountability for all neuroscience-related activities. Patton's responsibilities include developing financial models, evaluating investment opportunities, and providing critical financial insights to support the business unit's objectives. The Chief Financial Officer collaborates extensively with R&D and commercial teams to advance the development and market introduction of neuroscience treatments. By optimizing financial resources, Kecia Patton directly contributes to Lilly's commitment to addressing complex neurological and psychiatric conditions through scientific advancement. This leadership ensures financial health for a critical therapeutic area.
Melissa King - Chief Financial Officer, Site, Lilly Api (Houston)
Melissa King, the Chief Financial Officer, Site, Lilly Api (Houston) at Lilly, directs financial operations and strategy for the Lilly API manufacturing site in Houston. This executive role involves overseeing all financial aspects of the API production facility, including budgeting, cost management, financial reporting, and capital allocation. King ensures adherence to financial regulations and drives efficiency in manufacturing processes through sound financial stewardship. The Chief Financial Officer collaborates with site leadership and corporate finance to optimize operational performance and profitability. Melissa King's financial expertise is crucial for maintaining the integrity and efficiency of the Houston API site, a key component of Lilly's global manufacturing network and its commitment to producing high-quality pharmaceutical ingredients.
Dima Glikman - Chief Financial Officer, Cluster (Israel)
Dima Glikman, the Chief Financial Officer, Cluster (Israel) at Lilly, manages financial operations and strategic planning for Lilly's cluster operations in Israel. This executive role encompasses overseeing all financial activities, including budgeting, forecasting, financial reporting, and compliance within the designated region. Glikman ensures robust financial controls and drives fiscal performance to support Lilly's business objectives in Israel. The Chief Financial Officer collaborates with local leadership and corporate finance to optimize resource allocation and identify growth opportunities. Dima Glikman's financial leadership is critical for navigating the market dynamics in Israel and contributing to Lilly's global mission of delivering innovative medicines to patients worldwide. This role supports regional business success.
Delia Dragon - Executive Director and Chief Operating Officer Eli Lilly SSC
Delia Dragon, the Executive Director and Chief Operating Officer Eli Lilly SSC at Lilly, oversees the operational strategy and execution for the Eli Lilly Shared Services Center (SSC). This senior leadership position involves managing a broad range of business support functions, including finance, human resources, procurement, and IT services, to ensure efficiency and effectiveness across the organization. Dragon drives process improvements, implements best practices, and fosters a culture of continuous innovation within the SSC. The Chief Operating Officer ensures that shared services deliver high-quality, cost-effective support to Lilly's global business units. Delia Dragon's operational leadership is fundamental to optimizing Lilly's internal operations and enabling the company to focus on its core mission of developing life-changing medicines.
Hideyuki Tozaki - Director, Research & Development & Chief Operating Officer, Oncology
Hideyuki Tozaki, the Director, Research & Development & Chief Operating Officer, Oncology at Lilly, directs critical aspects of research and development operations within the oncology therapeutic area, alongside overseeing operational execution. This dual executive role involves guiding the strategic direction of oncology R&D programs and ensuring efficient operational management of related projects and resources. Tozaki's responsibilities include advancing the oncology pipeline, managing R&D budgets, and implementing operational improvements to accelerate drug discovery and development. The Chief Operating Officer function ensures seamless integration of scientific innovation with effective project execution. Hideyuki Tozaki's leadership is pivotal in advancing Lilly's commitment to developing groundbreaking oncology treatments for patients globally.
Elizabeth van Gelder - Senior Director, Information Technology & Business Units & Special Projects Chief of Staff
Elizabeth van Gelder, the Senior Director, Information Technology & Business Units & Special Projects Chief of Staff at Lilly, provides strategic leadership across information technology, business unit alignment, and special initiatives. This multifaceted role involves ensuring IT systems effectively support business objectives and driving cross-functional collaboration for key projects. Van Gelder's responsibilities include overseeing IT strategy implementation, managing project portfolios, and acting as a central point of contact for critical business unit needs. The Chief of Staff function ensures operational efficiency and strategic execution across diverse areas. Elizabeth van Gelder's leadership facilitates seamless integration of technology solutions and strategic planning, directly supporting Lilly's mission to develop and deliver innovative medicines. This executive function enhances operational agility and project success.
Karolina Patocki - Head Chief Marketing Officer, Lilly & Oncology Business Unit (Canada)
Karolina Patocki, the Head Chief Marketing Officer, Lilly & Oncology Business Unit (Canada) at Lilly, directs all marketing strategies and commercial execution for the oncology business unit within Canada. This senior leadership role involves developing and implementing comprehensive marketing plans to drive product awareness, market penetration, and revenue growth for oncology therapies. Patocki oversees market analysis, brand management, and promotional activities, ensuring alignment with global marketing objectives and Canadian regulatory requirements. The Chief Marketing Officer collaborates closely with sales, medical affairs, and market access teams to achieve commercial success. Karolina Patocki's strategic marketing leadership is essential for reaching patients and healthcare providers with critical oncology treatments, reinforcing Lilly's commitment to fighting cancer.
Roberto Servi - Global Senior VP, Marketing & Chief Marketing Officer, Neuroscience Business Unit
Roberto Servi, the Global Senior VP, Marketing & Chief Marketing Officer, Neuroscience Business Unit at Lilly, leads global marketing efforts for the neuroscience division. This executive position involves shaping the strategic direction of marketing for all neuroscience products worldwide, driving brand development, and ensuring effective market engagement. Servi oversees the creation and execution of global marketing campaigns, market access strategies, and commercial planning to maximize the impact of Lilly's neuroscience portfolio. The Chief Marketing Officer works in close partnership with R&D, regulatory affairs, and regional commercial teams to bring innovative treatments to patients. Roberto Servi's leadership ensures that Lilly's neuroscience medicines reach the global patient populations who need them most, advancing care for neurological and psychiatric disorders.
Tracy Huang - Senior Secretary To Chief Information Officer
Tracy Huang, the Senior Secretary To Chief Information Officer at Lilly, provides comprehensive administrative and operational support to the Chief Information Officer. This critical role ensures the smooth functioning of the CIO's office, managing schedules, coordinating meetings, and facilitating communication across the IT department and other business units. Huang's responsibilities include preparing documentation, organizing information flow, and handling sensitive correspondence to support strategic IT initiatives. The executive support function is vital for enabling the CIO to focus on technology strategy and digital transformation efforts. Tracy Huang's diligent support is instrumental in maintaining operational efficiency within the IT leadership structure, contributing to Lilly's overall technological advancement and business objectives.
Explore Leadership Teams in Manufacturing
Founded in 2020, Viatris empowers people worldwide to live healthier at every stage of life. They provide access to medicines, advance sustainable operations, develop innovative solutions, and leverage their collective expertise to improve patient health. Viatris is headquartered in Canonsburg, Pennsylvania.
Company Leadership
PC
Boehringer Ingelheim is a privately held, research-driven pharmaceutical company headquartered in Ingelheim am Rhein, Germany, founded in 1885. The company researches, develops, and manufactures prescription medicines and healthcare products across three core business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Its primary therapeutic focus areas include respiratory diseases, oncology, immunology, cardiometabolic conditions, and central nervous system disorders. Boehringer Ingelheim also develops and manufactures veterinary products for companion animals, livestock, and poultry. Operating in over 100 countries with more than 53,000 employees globally, the company maintains a broad network of research, manufacturing, and commercial sites across Europe, North America, and Asia. It is one of the largest privately owned pharmaceutical companies in the world.
Company Leadership DM
EM
BH
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Leadership ES
SS
BH
Alexion is a global biopharmaceutical company focused on the discovery, development, and commercialization of medicines for severe and life-threatening rare disorders. The company was established in 1992 and is headquartered in Boston, Massachusetts.
Company Leadership SG
PC
MO
YS
Frequently Asked Questions Regarding Lilly Top Executives and Leadership Team
Unlock more people and company data
